Quarterly Activities Report and Appendix 4C
Filed with ASX ·
6ix is reading this filing.
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- TRP-8803 60-Minute Infusion Achieved in Phase 2 BED Study
- All Patients Improve, 50% Achieve 12-Week BED Remission
- Appendix 4E and 2026 Annual Report
- Entropy Advances TRP-8803 to US Phase 2 in Depression
- TRP 8803 manufacturing secured for Phase 2/3 advancement
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics